AnaptysBio to abandon eczema drug development after mid-stage trial failure (updated)

AnaptysBio

11/12/2024 13:48

(Adds shares in paragraph 2, details throughout)
       Dec 11 (Reuters) - AnaptysBio  ANAB.O  said on Wednesday
it would end the development of its eczema drug after it failed
to meet the main and secondary goals of a mid-stage trial.
    The company's shares were halted during premarket trade.
    The drug, ANB032, did not meet the primary goal of the
proportion of patients who achieved at least a 75% improvement
from baseline on an eczema severity index.
    The company will focus on the rest of its autoimmune
portfolio, which includes drugs for rheumatoid arthritis and a
type of inflammatory bowel disease, CEO Daniel Faga said in a
statement.
    

 (Reporting by Puyaan Singh in Bengaluru; Editing by Sriraj
Kalluvila)
 ((Puyaan.Singh@thomsonreuters.com;))